Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: A report of 12 cases

被引:91
作者
Coghlan, ME
Sommadossi, JP
Jhala, NC
Many, WJ
Saag, MS
Johnson, VA
机构
[1] Univ Alabama, Sch Med, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA
[2] Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL USA
[3] Univ Alabama, Sch Med, Dept Anat Pathol, Birmingham, AL USA
[4] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA
关键词
D O I
10.1086/323783
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We retrospectively investigated the clinical and histopathologic features of hospitalized patients infected with human immunodeficiency virus who had symptomatic lactic acidosis syndrome at a university teaching hospital during 1995-2000. Twelve patients were identified, 11 during 1998-2000; of these, 5 died with rapid progression to otherwise unexplained multiple-organ failure. All had extensive prior exposure to nucleoside analog reverse-transcriptase inhibitors (NRTIs). At presentation, the most commonly identified NRTI component of antiretroviral regimens was stavudine plus didanosine. Eleven patients presented with abdominal pain, nausea, and/or emesis. Eight patients had prior acute weight loss (mean [+/- SD],12 +/- 5.3 kg). Median venous plasma lactate levels were greater than or equal to2-fold greater than the upper limit of normal (2.1 mmol/L). Serum transaminase levels were near normal limits at presentation. Histopathologic studies confirmed hepatic macrovesicular and microvesicular steatosis in 6 patients. Concurrent chemical pancreatitis was identified in 6 patients. The increasing number of cases identified during the study period suggests that physicians better recognize symptomatic lactic acidosis and/or that cumulative NRTI exposure may increase the risk for this syndrome.
引用
收藏
页码:1914 / 1921
页数:8
相关论文
共 26 条
[1]   FULMINANT-HEPATITIS WITH SEVERE LACTATE ACIDOSIS IN HIV-INFECTED PATIENTS ON DIDANOSINE THERAPY [J].
BISSUEL, F ;
BRUNEEL, F ;
HABERSETZER, F ;
CHASSARD, D ;
COTTE, L ;
CHEVALLIER, M ;
BERNUAU, J ;
LUCET, JC ;
TREPO, C .
JOURNAL OF INTERNAL MEDICINE, 1994, 235 (04) :367-371
[2]   Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [J].
Brinkman, K ;
ter Hofstede, HJM ;
Burger, DM ;
Smeitinkt, JAM ;
Koopmans, PP .
AIDS, 1998, 12 (14) :1735-1744
[3]   A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].
Carr, A ;
Miller, J ;
Law, M ;
Cooper, DA .
AIDS, 2000, 14 (03) :F25-F32
[4]   Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion [J].
Chariot, P ;
Drogou, I ;
de Lacroix-Szmania, I ;
Eliezer-Vanerot, MC ;
Chazaud, B ;
Lombès, A ;
Schaeffer, A ;
Zafrani, ES .
JOURNAL OF HEPATOLOGY, 1999, 30 (01) :156-160
[5]   LACTIC-ACIDOSIS COMPLICATING THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
CHATTHA, G ;
ARIEFF, AI ;
CUMMINGS, C ;
TIERNEY, LM .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (01) :37-39
[6]  
CHEN CH, 1991, MOL PHARMACOL, V39, P625
[7]   CELLULAR AND MOLECULE EVENTS LEADING TO MITOCHONDRIAL TOXICITY OF 1-(2-DEOXY-2-FLUORO-1-BETA-D-ARABINOFURANOSYL)-5-LODOURACIL IN HUMAN LIVER-CELLS [J].
CUI, LX ;
YOON, SY ;
SCHINAZI, RF ;
SOMMADOSSI, JP .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (02) :555-563
[8]   Riboflavin to treat nucleoside analogue-induced lactic acidosis [J].
Fouty, B ;
Frerman, F ;
Reves, R .
LANCET, 1998, 352 (9124) :291-292
[9]  
HAVLIR D, 2000, 7 C RETR OPP INF
[10]   MITOCHONDRIAL TOXICITY OF ANTIVIRAL DRUGS [J].
LEWIS, W ;
DALAKAS, MC .
NATURE MEDICINE, 1995, 1 (05) :417-422